Validation of Artificial Intelligence Enabled TB Screening and Diagnosis in Zambia

NCT ID: NCT05139940

Last Updated: 2025-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2432 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-22

Study Completion Date

2022-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculosis (TB) is a global epidemic and for many years has remained a major cause of death throughout the developing world. Zambia is among the top 30 TB/HIV high burden countries. Chest X-ray (CXR) is recommended as a triaging test for TB, and a diagnostic aid when available. However, many high-burden settings lack access to experienced radiologists capable of interpreting these images, resulting in mixed sensitivity, poor specificity, and large inter-observer variation. In recognition of this challenge, the World Health Organization has recommended the use of automated systems that utilize artificial intelligence (AI) to read CXRs for screening and triaging for TB. In this study, we primarily evaluate the performance of our AI algorithm for TB, and secondarily for Abnormal/Normal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pilot Group to calibrate the operating points for AI algorithms (Estimated Enrollment up to 500)

Diagnostic Test: TB AI algorithm performance in detecting active TB.

Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)

Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.

Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.

Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count.

No interventions assigned to this group

Main Cross Sectional Group (Estimated Enrollment 1932 minus the volume in pilot)

Diagnostic Test: TB AI algorithm performance in detecting active TB.

Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)

Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.

Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.

Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who are 18 years and older with a known HIV status or are willing to undergo HIV testing if unknown HIV status and meet the following criteria will be included in the study:

* Presumptive TB patients defined as having any of the following:

○ Cough, Weight loss, Night sweats, Fever
* Household /close TB contacts regardless of symptoms
* Newly diagnosed HIV regardless of symptoms.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre for Infectious Disease Research in Zambia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chainda South Health Facility

Lusaka, Lusaka Province, Zambia

Site Status

Chawama first level hospital

Lusaka, Lusaka Province, Zambia

Site Status

Kanyama level 1

Lusaka, Lusaka Province, Zambia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Zambia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Google AI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Host Blood RNA Signatures for Diagnosis of TB
NCT05542511 ACTIVE_NOT_RECRUITING